Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

ROOPA INDUSTRIES LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹42.60
at close · 28 Oct 2026
▼ 0.39 (-0.91%)

Latest filings

  1. No physical share transfer requests in Aug and Sep 2026 · Compliance
  2. Routine demat compliance certificate filed for Q2 FY27 · Compliance
  3. 41st AGM voting results: all 5 resolutions passed · Board & Shareholder Meetings
All filings ↓
Ask Nexa about ROOPA INDUSTRIES LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹126 Cr over the trailing twelve months.

Market Cap
₹34 Cr
P / E (TTM)
213.0×
EV / EBITDA
14.9×
Div Yield
—
Growth
36.8%▲
Revenue 5y CAGR
PAT -35.0% · EBITDA +8.4%
Quality
21.6%▲
ROCE (5y median)
ROE 9.7% (5y median) · margin 3.3%
Leverage
1.76·
Debt / Equity · high
Net debt ₹31 Cr
Revenue FY21→FY26
4.8×▲
Margin −2.6 pts
₹27 Cr → ₹128 Cr
Cash conversion
1.51×▲
Operating cash ÷ profit · 5 yrs
₹9 Cr on ₹6 Cr
Moves on a normal day
2.27%·
Median daily move
Last 258 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#153/158
P/B#50/163
ROCE#150/183
ROE#139/166
Debt / Equity#160/166
EBITDA margin#141/165
Revenue growth#128/161
Profit growth#91/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 37% a year over 5 years
Returns on capital 21.6% (5-year median)
#150 of 183 in Pharmaceuticals on the latest reported figures · up from 9.6% in FY21
Over 5 years it reported ₹6.00 Cr of profit and ₹9.05 Cr of operating cash — 1.51×
Profit is converting into cash
Concerns
Profit shrinking over 5 years (−35% a year)
Carries more debt than its peers — 1.76× equity
higher than 96% of its 166 Pharmaceuticals peers

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from ROOPA INDUSTRIES LTD.'s filed financials and exchange disclosures

What does ROOPA INDUSTRIES LTD. do?

ROOPA INDUSTRIES LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is ROOPA INDUSTRIES LTD. profitable?

Yes. Over the trailing twelve months ROOPA INDUSTRIES LTD. reported a net profit of ₹0.13 Cr on revenue of ₹126 Cr.

Does ROOPA INDUSTRIES LTD. pay a dividend?

Not in the latest reported year — ROOPA INDUSTRIES LTD.'s dividend payout for FY26 was nil.

Is ROOPA INDUSTRIES LTD. debt-free?

No. It reported borrowings of ₹31 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹31 Cr after cash. Debt stands at 1.76× equity. That is higher than 96% of its 166 Pharmaceuticals peers.

Is ROOPA INDUSTRIES LTD. expensive compared with its peers?

On trailing P/E, ROOPA INDUSTRIES LTD. ranks 153 of 158 in Pharmaceuticals — cheaper than 3% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the ROOPA INDUSTRIES LTD. share price move in a day?

On a typical session ROOPA INDUSTRIES LTD. moves 2.27% — that is the median absolute close-to-close move across its last 258 trading days. MarketPing measures each filing's price reaction against it.

Where can I track ROOPA INDUSTRIES LTD.'s announcements?

Every NSE and BSE filing by ROOPA INDUSTRIES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.